Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT04451954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult Subjects
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
July 2, 2020
Completion date
September 20, 2021
Enrollment
210 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, influenza immunisation